- List
- By Topic
- On Map
- Search Details

CAR | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma"
Need help? See RSS Feeds
Choose a feed type:

CAR | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma" (49 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03271632 | Recruiting | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03271632 | GIMI-IRB-17013 | July 15, 2017 | December 31, 2019 | December 31, 2020 | September 5, 2017 | February 26, 2018 |
|
|||
2 | NCT03322735 | Recruiting | Study of BCMA CAR-T in Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
10 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03322735 | HenanCH284 | December 8, 2017 | October 2018 | December 2019 | October 26, 2017 | December 29, 2017 |
|
|||
3 | NCT03751293 | Not yet recruiting | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
10 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03751293 | 0203-001 | November 30, 2018 | July 30, 2019 | July 30, 2020 | November 22, 2018 | November 22, 2018 |
|
|||
4 | NCT03559764 | Not yet recruiting | Study of BCMA CAR-T in Multiple Myeloma |
|
|
Interventional |
Early Phase 1 |
|
Industry |
|
|
20 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03559764 | BCMA CAR T-HNRM-01 | June 2018 | February 2020 | May 2020 | June 18, 2018 | June 18, 2018 | ||||
5 | NCT03815383 | Not yet recruiting New |
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
12 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03815383 | 0203-008 | February 2019 | January 2021 | April 2021 | January 24, 2019 | January 24, 2019 |
|
|||
6 | NCT03070327 | Recruiting | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03070327 | 17-025 | February 27, 2017 | February 2020 | February 2020 | March 3, 2017 | September 10, 2018 |
|
|||
7 | NCT03672318 | Recruiting | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
33 | All | 18 Years and older (Adult, Older Adult) | NCT03672318 | LCCC 1603-ATL | January 14, 2019 | November 2020 | October 2032 | September 14, 2018 | February 20, 2019 |
|
|||
8 | NCT03758417 | Not yet recruiting | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03758417 | CR108494 68284528MMY2002 |
January 21, 2019 | July 20, 2020 | April 21, 2022 | November 29, 2018 | November 29, 2018 |
|
|||
9 | NCT03464916 | Recruiting | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
72 | All | 18 Years and older (Adult, Older Adult) | NCT03464916 | SOR-CART-MM-001 | April 5, 2018 | April 2020 | September 1, 2020 | March 14, 2018 | June 27, 2018 |
|
|||
10 | NCT03767751 | Recruiting | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
80 | All | 12 Years to 70 Years (Child, Adult, Older Adult) | NCT03767751 | CHN-PLAGH-BT-037 | December 5, 2018 | December 5, 2022 | December 5, 2022 | December 7, 2018 | December 7, 2018 |
|
|||
11 | NCT03380039 | Recruiting | Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma |
|
|
Interventional |
Not Applicable |
|
Other / Industry |
|
|
12 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03380039 | XH-17-018 | October 13, 2017 | September 30, 2019 | September 30, 2020 | December 20, 2017 | December 20, 2017 |
|
|||
12 | NCT03287804 | Recruiting | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03287804 | AUTO2-MM1 2016-003893-42 |
APRIL | May 5, 2017 | October 2020 | October 2020 | September 19, 2017 | July 10, 2018 |
|
||
13 | NCT03288493 | Recruiting | P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03288493 | P-BCMA-101-001 | September 20, 2017 | December 31, 2018 | June 30, 2021 | September 20, 2017 | November 14, 2018 |
|
|||
14 | NCT03661554 | Recruiting | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma |
|
|
Interventional |
Early Phase 1 |
|
Industry / Other |
|
|
15 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03661554 | PRG 1801 | BCMA CAR-T | April 10, 2018 | October 30, 2018 | November 30, 2018 | September 7, 2018 | September 7, 2018 |
|
||
15 | NCT03716856 | Recruiting | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
12 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03716856 | CG6003 | December 26, 2017 | April 30, 2019 | August 31, 2020 | October 23, 2018 | October 23, 2018 |
|
|||
16 | NCT03448978 | Recruiting | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
15 | All | 18 Years and older (Adult, Older Adult) | NCT03448978 | 241-59-88 | February 26, 2018 | February 26, 2019 | March 1, 2020 | February 28, 2018 | November 7, 2018 |
|
|||
17 | NCT03602612 | Recruiting | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
NIH |
|
|
42 | All | 18 Years to 73 Years (Adult, Older Adult) | NCT03602612 | 180125 18-C-0125 |
September 14, 2018 | January 1, 2023 | January 1, 2024 | July 27, 2018 | January 23, 2019 |
|
|||
18 | NCT03502577 | Recruiting | BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
18 | All | 21 Years and older (Adult, Older Adult) | NCT03502577 | 9952 NCI-2018-00514 P30CA015704 RG9218033 |
May 23, 2018 | July 30, 2021 | July 30, 2034 | April 18, 2018 | February 11, 2019 |
|
|||
19 | NCT03664661 | Recruiting | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
15 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03664661 | HenanCH CAR 2-2 | April 11, 2018 | April 10, 2019 | April 30, 2020 | September 10, 2018 | September 10, 2018 |
|
|||
20 | NCT03710421 | Not yet recruiting | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03710421 | 17403 NCI-2018-02022 |
June 10, 2019 | December 10, 2021 | December 10, 2021 | October 18, 2018 | January 29, 2019 |
|
|||
21 | NCT03093168 | Recruiting | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
10 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03093168 | anti-BCMA CART | February 15, 2017 | September 2019 | February 2020 | March 28, 2017 | September 27, 2018 |
|
|||
22 | NCT03473496 | Recruiting | CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Older Adult) | NCT03473496 | 2017-XYNK-003 | MM | March 1, 2018 | December 31, 2021 | December 31, 2022 | March 22, 2018 | April 18, 2018 |
|
||
23 | NCT03711864 | Recruiting | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
15 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03711864 | YMCART201804 | October 10, 2018 | October 10, 2020 | December 20, 2020 | October 19, 2018 | October 19, 2018 |
|
|||
24 | NCT03706547 | Not yet recruiting | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
20 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03706547 | SHZS-MM002 | October 30, 2018 | July 2020 | December 2021 | October 16, 2018 | October 16, 2018 |
|
|||
25 | NCT03548207 | Recruiting | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
84 | All | 18 Years and older (Adult, Older Adult) | NCT03548207 | CR108480 2018-000121-32 68284528MMY2001 |
June 29, 2018 | September 14, 2021 | September 14, 2021 | June 7, 2018 | February 1, 2019 |
|
|||
26 | NCT03338972 | Recruiting | Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry / NIH |
|
|
25 | All | 22 Years and older (Adult, Older Adult) | NCT03338972 | 9762 NCI-2017-01932 P30CA015704 |
November 29, 2017 | December 15, 2020 | December 15, 2022 | November 9, 2017 | March 27, 2018 |
|
|||
27 | NCT03430011 | Recruiting | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
118 | All | 18 Years and older (Adult, Older Adult) | NCT03430011 | H125001 | EVOLVE | February 1, 2018 | March 2021 | March 2021 | February 12, 2018 | February 11, 2019 |
|
||
28 | NCT03274219 | Recruiting | Study of bb21217 in Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Older Adult) | NCT03274219 | CRB-402 | August 16, 2017 | June 2020 | June 2020 | September 6, 2017 | February 4, 2019 |
|
|||
29 | NCT02954445 | Recruiting | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
45 | All | 14 Years to 75 Years (Child, Adult, Older Adult) | NCT02954445 | TMMU-BTC-009 | October 2016 | October 2019 | October 2020 | November 3, 2016 | January 23, 2018 |
|
|||
30 | NCT03312205 | Recruiting | CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry / Other |
|
|
50 | All | 1 Year to 70 Years (Child, Adult, Older Adult) | NCT03312205 | daopeicart | August 29, 2017 | August 29, 2019 | August 29, 2023 | October 17, 2017 | January 9, 2019 |
|
|||
31 | NCT03601078 | Recruiting | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
181 | All | 18 Years and older (Adult, Older Adult) | NCT03601078 | BB2121-MM-002 U1111-1216-4209 2018-000264-28 |
KarMMa-2 | December 13, 2018 | March 12, 2025 | March 12, 2025 | July 26, 2018 | February 8, 2019 |
|
||
32 | NCT00881920 | Recruiting | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
54 | All | 18 Years and older (Adult, Older Adult) | NCT00881920 | H-23574-CHARKALL CHARKALL |
CHARKALL | July 2009 | July 2019 | July 2034 | April 15, 2009 | February 28, 2018 |
|
||
33 | NCT03767725 | Recruiting | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
10 | All | 14 Years to 75 Years (Child, Adult, Older Adult) | NCT03767725 | Weihong Chen06082018 | June 2, 2018 | June 1, 2021 | September 1, 2021 | December 7, 2018 | December 10, 2018 |
|
|||
34 | NCT03549442 | Recruiting | Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT03549442 | 828773 | May 9, 2018 | May 2020 | May 2021 | June 8, 2018 | June 20, 2018 |
|
|||
35 | NCT03752541 | Recruiting | Efficacy and Safety Evaluation of BCMA-UCART |
|
|
Interventional |
Not Applicable |
|
Industry / Other |
|
|
20 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03752541 | 2018-CAR-00CH3 | November 20, 2018 | November 20, 2019 | November 20, 2020 | November 26, 2018 | November 27, 2018 |
|
|||
36 | NCT03155100 | Recruiting | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
40 | All | 18 Years to 74 Years (Adult, Older Adult) | NCT03155100 | NMSG#24/15 2016-001178-13 |
KEd | August 7, 2017 | June 21, 2020 | June 30, 2023 | May 16, 2017 | January 8, 2019 |
|
||
37 | NCT03104270 | Recruiting | Combination Study for High Risk Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03104270 | CA204-187 | March 13, 2017 | February 2020 | May 2020 | April 7, 2017 | January 8, 2019 |
|
|||
38 | NCT03018405 | Recruiting | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
146 | All | 18 Years and older (Adult, Older Adult) | NCT03018405 | CYAD-N2T-002 | THINK | December 2016 | May 2021 | August 2021 | January 12, 2017 | November 26, 2018 |
|
||
39 | NCT03651128 | Not yet recruiting | Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
381 | All | 18 Years and older (Adult, Older Adult) | NCT03651128 | BB2121-MM-003 U1111-1217-9988 2018-001023-38 |
KarMMa-3 | November 30, 2018 | June 9, 2025 | June 9, 2025 | August 29, 2018 | October 25, 2018 |
|
||
40 | NCT03492268 | Recruiting | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma |
|
|
Interventional |
Not Applicable |
|
Industry / Other |
|
|
20 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03492268 | 2018-CART-00CH3(1) | November 20, 2018 | November 20, 2019 | December 1, 2020 | April 10, 2018 | November 27, 2018 |
|
|||
41 | NCT02970747 | Recruiting | Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone in Multiple Myeloma Patients |
|
|
Observational |
|
Industry |
|
|
300 | All | 18 Years and older (Adult, Older Adult) | NCT02970747 | IOM-070337 | CARO | October 25, 2016 | April 2021 | April 2022 | November 22, 2016 | December 20, 2018 |
|
|||
42 | NCT03196414 | Recruiting | Study of CART-138/BCMA Therapy for R/R Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
10 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03196414 | myeloma-01 | September 2016 | September 2026 | December 2026 | June 22, 2017 | June 22, 2017 |
|
|||
43 | NCT02294357 | Recruiting | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Older Adult) | NCT02294357 | IST-CAR-2014-100701 (20159897) | December 2014 | November 2018 | December 2018 | November 19, 2014 | October 5, 2018 |
|
|||
44 | NCT03455972 | Recruiting | Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
10 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03455972 | myeloma-03 | April 1, 2018 | April 1, 2028 | April 1, 2029 | March 7, 2018 | March 7, 2018 |
|
|||
45 | NCT01464034 | Recruiting | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
117 | All | 18 Years and older (Adult, Older Adult) | NCT01464034 | AMyC 10-MM-01 IST-CAR-521 PO-MM-PI-0034 |
November 2011 | December 2017 | June 2018 | November 3, 2011 | October 18, 2017 |
|
|||
46 | NCT03638206 | Recruiting | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry / Other |
|
|
73 | All | 4 Years to 70 Years (Child, Adult, Older Adult) | NCT03638206 | 2018ZDYFY-BinDeDBD | March 1, 2018 | March 1, 2023 | March 1, 2023 | August 20, 2018 | August 20, 2018 |
|
|||
47 | NCT03302403 | Not yet recruiting | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors |
|
|
Interventional |
Not Applicable |
|
Other / Industry |
|
|
48 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03302403 | CGZ001 | October 2017 | June 2019 | December 2020 | October 5, 2017 | October 5, 2017 |
|
|||
48 | NCT02529813 | Recruiting | CD19+ CAR T Cells for Lymphoid Malignancies |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
30 | All | 1 Year to 80 Years (Child, Adult, Older Adult) | NCT02529813 | 2013-1018 NCI-2015-01492 |
December 2015 | December 2021 | December 2021 | August 20, 2015 | January 14, 2019 |
|
|||
49 | NCT01746849 | Recruiting | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
93 | All | 18 Years to 60 Years (Adult) | NCT01746849 | 12-077 | December 2012 | December 2019 | December 2019 | December 11, 2012 | October 26, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.